STAT

DECEMBER 13, 2023

Pfizer said Wednesday that its 2024 profits would fall far below investor expectations, leading shares to tumble 7% in early trading. Its shares have fallen 45% and it has struggled to maintain the momentum it achieved during the pandemic with the development of one of two widely used Covid vaccines and a Covid treatment, Paxlovid.

Vaccines 108

Vaccines 108

Pharmacy Times

SEPTEMBER 25, 2023

For community pharmacists, cooler temperatures, school buses on the roads and Friday night football are not just signs of a changing season – they are indicators that patients will soon be seeking vaccinations for the 2023-2024 respiratory illness season.

Vaccines 148

Vaccines Immunization 148

Fierce Pharma

MAY 2, 2024

With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based biopharma is busy laying the groundwork for its next potential mRNA shot in | Moderna currently expects initial approvals of its RSV vaccine to start rolling in during the first half of 2024, the company said Thursday.

Vaccines 101

Vaccines Immunization 101

Pharmafile

MAY 13, 2024

Moderna has announced that the US Food and Drug Administration (FDA) has shared that it will not complete its review of the Biologics License Agreement (BLA) for mRNA-1345 by its Prescription Drug User Fee Act (PDUFA) date of 12 May 2024. The post Moderna shares update on RSV vaccine appeared first on Pharmafile.

Vaccines 52

Vaccines FDA 52

Fierce Pharma

APRIL 26, 2024

GSK pulls Pfizer and BioNTech into another vaccine patent lawsuit, this time surrounding the partners' mRNA-based COVID shots fkansteiner Fri, 04/26/2024 - 10:07

Vaccines 102

Vaccines 102

STAT

OCTOBER 5, 2023

The Food and Drug Administration’s expert vaccine advisory panel on Thursday unanimously endorsed the idea of taking a strain of influenza viruses that no longer appears to circulate out of flu shots as quickly as possible, pressing the FDA and manufacturers to try to get the work done on an expedited timeline. Read the rest…

Vaccines 140

Vaccines FDA 140

Digital Pharmacist

AUGUST 21, 2023

As we gear up for the upcoming flu season of 2023-2024, it’s important to reflect on the lessons of the previous year , and understand how the coming year may look different. The most effective preventive measure against the flu is getting an annual flu vaccine. According to the CDC, in the 2023-2024 season, the U.S.

Vaccines 98

Vaccines Communication Immunization 98

Pharmacy Times

OCTOBER 3, 2023

NVX-CoV2601 vaccine adjuvanted 2023-2024 formula granted EUA for the prevention of COVID-19 in those 12 years of age and older.

Vaccines 145

Vaccines FDA 145

European Pharmaceutical Review

FEBRUARY 26, 2024

At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines. CHMP meeting highlights: January 2024 The post CHMP meeting highlights: February 2024 appeared first on European Pharmaceutical Review.

Generic Medicine 88

Generic Medicine Pharmaceutical Companies Pharmaceutical Companies Vaccines 88

Pharmaceutical Technology

OCTOBER 13, 2023

The Phase IIb SurVaxM vaccine study will enrol 265 patients and has an estimated completion date in Q2 2024.

Vaccines 111

Vaccines FDA 111

Pharmaceutical Technology

SEPTEMBER 12, 2023

adapted monovalent Covid-19 vaccine, COMIRNATY 2023-2024 Formulation. The US FDA has approved Pfizer and BioNTech’s sBLA for Omicron XBB.1.5-adapted

Vaccines 111

Vaccines FDA 111

Pharmaceutical Technology

MARCH 8, 2024

The company revealed the data at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference 2024.

Vaccines 59

Vaccines 59

Fierce Pharma

JANUARY 30, 2024

After 'bad launch' remark by CEO, Pfizer's RSV vaccine gains traction in Q4. kdunleavy Tue, 01/30/2024 - 08:58 How will it fare in latest round of GSK showdown?

Vaccines 108

Vaccines 108

European Pharmaceutical Review

OCTOBER 4, 2023

The World Health Organization ( WHO ) has recommended a new vaccine, R21/Matrix-M, to prevent malaria in children. The R21 vaccine is the second malaria vaccine recommended by WHO. This follows the WHO’s recommendation of the RTS,S/AS01 vaccine for the disease in 2021.

Vaccines 99

Vaccines 99

European Pharmaceutical Review

DECEMBER 18, 2023

billion ($260 million) to establish a state-of-the-art research and vaccine development initiative in Denmark. Research at the Novo Nordisk Foundation Initiative for Vaccines and Immunity, or NIVI, will focus initially on creating new or improved vaccines for tuberculosis, influenza , and Group A Streptococcus (GAS).

Vaccines 91

Vaccines Immunization 91

Digital Pharmacist

SEPTEMBER 20, 2023

The Medicare Open Enrollment period for 2024 is quickly approaching – this is a critical time for both your patients and your pharmacy. Below is a breakdown of what you need to be aware of when assisting patients with 2024 open enrollments, as well as a few tips on how your pharmacy can prepare for this busy time at the pharmacy.

Independent Pharmacies 105

Independent Pharmacies Insurance Nursing Homes Immunization 105

Pharma Mirror

JANUARY 19, 2024

As we step into 2024, the global life science industry finds itself at a crossroads, facing plenty of challenges alongside an abundance of exciting opportunities. The pharmaceutical and contract outsourcing space has shifted, with new trends emerging that will shape the future of this rapidly changing industry.

Vaccines 52

Vaccines 52

Fierce Pharma

OCTOBER 24, 2023

On the market for two decades, AstraZeneca’s nasal spray flu vaccine, FluMist, may become available for self-administration as soon as next year. | On the market for two decades, AstraZeneca’s nasal spray flu vaccine, FluMist, may become available for self-administration as soon as next year.

Vaccines 96

Vaccines FDA 96

PioneerRx

MARCH 19, 2024

The next, you’re answering phone calls or submitting vaccination claims. Pharmacy work is demanding. One minute you’re at the drive thru. A day in the pharmacy.

Vaccines 105

Vaccines 105

European Pharmaceutical Review

JANUARY 10, 2024

A lymph node-targeted cancer vaccine has shown potential to prevent relapse of KRAS-mutated pancreatic and colorectal cancers in patients who have had surgery, according to a Phase I trial led by US researchers. Patients were given no more than 10 doses of the ELI-002 cancer vaccine targeted toward KRAS G12D and G12R mutations. “It

Vaccines 86

Vaccines Chemotherapy 86

Fierce Pharma

APRIL 4, 2024

Sanofi pledges to keep polio vaccine supplies afloat in India after new approval fkansteiner Thu, 04/04/2024 - 16:04

Vaccines 57

Vaccines 57

European Pharmaceutical Review

SEPTEMBER 12, 2023

A T-cell epitope cancer vaccine significantly improved overall survival in non-small cell lung cancer (NSCLC) compared to chemotherapy, Phase III data published in Annals of Oncology has shown. The cancer vaccine offered an overall survival of 11.1 months in patients who received Tedopi. months compared 7.5 months for standard of care.

Vaccines 98

Vaccines Chemotherapy Immunization 98

BioPharm

APRIL 17, 2024

The Xcellerex magnetic mixer, single-use mixing system was designed to address challenges in large-scale mAb, vaccine, and genomic medicine manufacturing processes.

Vaccines 72

Vaccines 72

Pharmaceutical Technology

OCTOBER 4, 2023

The US FDA has amended the EUA of Novavax’s adjuvanted Covid-19 vaccine (NVX-CoV2601) to incorporate the 2023-2024 formula.

Vaccines 69

Vaccines FDA 69

Fierce Pharma

FEBRUARY 28, 2024

As Novavax emerges from its “transition year” in 2023, the vaccine maker is still raising concerns among Wall Street investors in early 2024. | As Novavax emerges from its “transition year” in 2023, the vaccine maker is still raising concerns among Wall Street investors in early 2024.

Vaccines 96

Vaccines 96

Pharma Times

FEBRUARY 8, 2024

The committee has advised that the vaccine should be given to those at the highest risk

Vaccines 48

Vaccines 48

Pharmaceutical Technology

MARCH 28, 2024

According to the CDC, over 64 cases of measles have been documented in the US in 2024, already exceeding 2023's total of 58.

Documentation 113

Documentation Vaccines 113

PharmExec

DECEMBER 19, 2023

Merck’s Biologics License Application for V116, a novel 21-valent pneumococcal conjugate vaccine has been given a Prescription Drug User Fee Act (PDUFA) date of June 17, 2024.

Vaccines 52

Vaccines FDA 52

Pharmaceutical Commerce

DECEMBER 19, 2023

Merck’s Biologics License Application for V116, a 21-valent pneumococcal conjugate vaccine, was given a Prescription Drug User Fee Act (PDUFA) date of June 17, 2024.

Vaccines 52

Vaccines FDA 52

Hospital Pharmacy Europe

JUNE 23, 2023

The UK should introduce routine vaccination for respiratory syncytial virus (RSV) to protect babies and older adults, the Joint Committee on Vaccination and Immunisation (JCVI) has recommended. The post JCVI backs RSV routine vaccination for babies and older adults in the UK appeared first on Hospital Pharmacy Europe.

Vaccines 98

Vaccines Hospitals 98

Pharmacy Times

JULY 18, 2023

With the end of the national public health emergency for COVID-19 in May 2023, what can be expected as we look ahead to the 2023-2024 influenza season and beyond?

Vaccines 123

Vaccines 123

Drug Topics

FEBRUARY 8, 2024

June 7, 2024 is the target PDUFA date for the additional indication of GSK's respiratory syncytial virus vaccine Arexvy.

Vaccines 98

Vaccines FDA 98

Fierce Pharma

JANUARY 31, 2024

Beaten to the punch by Pfizer in developing a vaccine for COVID, GSK has regained some of its lost luster as a vaccine powerhouse with its advancement of respiratory syncytial virus (RSV) shot Arex | GSK's RSV vaccine Arexvy generated $1.5 billion in sales in 2023 compared to $890 million for Pfizer's Abrysvo.

Vaccines 116

Vaccines 116

Pharmaceutical Technology

AUGUST 30, 2023

Codagenix faces a late 2024 data readout following enrollment challenges in its paediatric RSV vaccine Phase I study.

Vaccines 52

Vaccines 52

PQA

APRIL 18, 2024

The upcoming 2024 PQA Annual Meeting's poster session will showcase 23 quality improvement and research projects. Sponsored by Pharmacy Quality Solutions, this session offers authors a platform to exhibit their work and enables attendees to engage in insightful discussions about healthcare quality.

Specialty Pharmacies 40

Specialty Pharmacies Community Pharmacies Vaccines 40

Pharmaceutical Technology

MAY 10, 2024

GlobalData examines four of the key trends affecting contract research organizations (CROs) involved with infectious diseases.

Vaccines 59

Vaccines 59

Drug Topics

NOVEMBER 23, 2023

The federal agencies said that they will continue to work closely with manufacturers to maintain the availability of the vaccines through the end of 2023 and early 2024 to meet the demand during the RSV season.

Vaccines 98

Vaccines FDA 98